HTL-0030310: A Novel Somatostatin Receptor Ligand for Endocrine Disorders

1. Executive Summary of HTL-0030310

HTL-0030310 is an investigational therapeutic agent, characterized as a novel somatostatin receptor ligand (SRL).[1] Its defining feature is a preferential selectivity for the somatostatin receptor subtype 5 (SSTR5) over subtype 2 (SSTR2), a distinction that sets it apart from many currently available SRLs and forms the basis of its therapeutic rationale.[1] Chemically, HTL-0030310 is a peptide, meticulously designed through computer-aided drug design (CADD), with the known cyclic hexapeptide SRL, pasireotide, serving as a structural starting point.[4] While some general communications have referred to it as a "small molecule" [6], its peptide nature is more accurately defined by detailed design disclosures and has implications for its pharmacokinetic profile, manufacturing, and potential immunogenicity.

The development of HTL-0030310 was undertaken by Sosei Heptares (now Nxera Pharma following a name change effective April 2024 [8]) utilizing their proprietary G protein-coupled receptor (GPCR) Structure-Based Drug Design (SBDD) platform.[6] The core hypothesis underpinning its development is that its SSTR5 selectivity will enable effective hormonal control in conditions such as Cushing's disease and acromegaly, potentially with an improved side-effect profile, particularly concerning growth hormone (GH) secretion (largely mediated by SSTR2) and glucose homeostasis.[1]

Initial investigations focused on its utility in Cushing's disease and acromegaly.[1] Following the completion of a Phase 1 clinical trial in healthy volunteers (NCT03847207 / EudraCT 2018-003169-33) [8], findings have suggested a potential expansion of its therapeutic application into hypoglycemic disorders.[4] This evolution in potential indications appears to be data-driven, reflecting observations from its early human studies.

Table 1: HTL-0030310 - Key Profile Summary

Feature	Description
Drug Name	HTL-0030310
Alternative Names	HTL0030310, HTL 0030310
Developer	Sosei Heptares (now Nxera Pharma)
Chemical Nature	Peptide; Somatostatin receptor 5 (SSTR5)-preferring agonist
Primary Mechanism	Selective SSTR5 agonism
Key Molecular Target(s)	SSTR5; activity also noted at SSTR3
Investigated Indications	Cushing's disease, Acromegaly, Endocrine disorders, Hypoglycemic conditions
Highest Reported Development Phase	Phase 1 Completed

2. Pharmacological Profile and Mechanism of Action

HTL-0030310 is a synthetic peptide designed as an agonist for somatostatin receptors (SSTRs), which are a family of five GPCR subtypes (SSTR1-5) involved in a wide array of physiological processes, including the regulation of endocrine and exocrine secretions, cell growth, and motility.[1]

Receptor Selectivity Profile – The Key Differentiator

The primary pharmacological characteristic of HTL-0030310 is its engineered selectivity for SSTR5 over SSTR2.[1] This contrasts with many established SRLs; for instance, octreotide and lanreotide predominantly target SSTR2, while pasireotide exhibits broader activity across SSTR1, 2, 3, and 5.[3] HTL-0030310 was specifically designed to introduce SSTR5 selectivity relative to SSTR2, using pasireotide as a chemical scaffold.[4] In addition to its SSTR5 preference, some evidence also points to selectivity for SSTR3 subtypes.[3]

This distinct selectivity profile has significant therapeutic implications. The expression of SSTR5 on ACTH- and GH-secreting pituitary adenomas, as well as on pancreatic islet cells (which regulate insulin and glucagon secretion), makes it a rational target for modulating hormone hypersecretion in related disorders.[1] The hypothesis that SSTR5 selectivity might minimize the inhibition of GH (an effect largely attributed to SSTR2 activation) could translate to a more favorable side-effect profile or offer advantages in specific clinical scenarios where potent SSTR2 agonism is not desired.[4] Furthermore, SSTR3 activation is often linked to anti-proliferative and apoptotic effects, which could confer additional benefits in the context of tumorous conditions.

Comparison with Pasireotide

Pasireotide, the multi-receptor SRL used as the starting point for HTL-0030310's design, has functional and binding activity at SSTR1, 2, 3, and 5.[3] HTL-0030310, while reportedly sharing a "very similar SST agonist signature to pasireotide" in a general sense, distinguishes itself through its high functional selectivity for SSTR5 over SSTR2.[4] This difference was highlighted in in vitro studies on ACTH-secreting adenomas, where the inhibitory effect of pasireotide (at 10 nM) on corticotropin-releasing hormone (CRH)-stimulated ACTH secretion appeared less pronounced than that observed with HTL-0030310.[3] This suggests that the refined selectivity of HTL-0030310 might translate to differentiated efficacy or tolerability.

Molecular Mechanism

As an SSTR5 agonist, HTL-0030310 binds to and activates SSTR5. This activation typically initiates intracellular signaling cascades common to SSTRs, including the inhibition of adenylyl cyclase, leading to a reduction in intracellular cyclic AMP (cAMP) levels. Downstream effects also involve the modulation of ion channel activity, such as the activation of K+ channels and inhibition of Ca2+ channels. Collectively, these molecular events culminate in decreased hormone synthesis and secretion from target cells and may also exert anti-proliferative effects.[2] The specific SSTR5-preferential agonism, potentially augmented by SSTR3 activity, aims to achieve desired clinical outcomes—such as the reduction of ACTH and cortisol in Cushing's disease, or GH and IGF-1 in acromegaly, or the modulation of insulin and glucagon in hypoglycemic states—with potentially greater precision and an improved therapeutic window compared to less selective SRLs. For instance, in the context of Cushing's disease, if SSTR5 is a more critical mediator of ACTH inhibition in certain patient populations, or if avoiding strong SSTR2 agonism mitigates specific side effects (like the hyperglycemia sometimes associated with pasireotide, which can result from a complex interplay of SSTR5-mediated insulin inhibition and SSTR2-mediated glucagon inhibition), HTL-0030310 could offer a distinct clinical advantage.

3. Development and Origin

HTL-0030310 was developed by Sosei Heptares [10], a company that has since been renamed Nxera Pharma as of April 2024.[8] The compound is a product of Sosei Heptares' proprietary GPCR Structure-Based Drug Design (SBDD) platform, marking the sixth molecule from this advanced platform to advance into clinical development.[7]

The design of HTL-0030310 was a highly rational process, employing computer-aided drug design (CADD). This involved the generation and utilization of peptide models bound to optimized homology models of both SSTR5 and SSTR2. The primary objective of this computational approach was to engineer specific selectivity for SSTR5 over SSTR2, thereby aiming for a differentiated pharmacological profile.[4] The use of such a sophisticated SBDD platform for a challenging GPCR target like SSTR5 underscores a commitment to understanding and exploiting target-ligand interactions at a molecular level. This approach is intended to yield drug candidates with enhanced specificity and potentially improved therapeutic properties compared to those identified through more traditional screening methodologies. The progression of multiple candidates from this platform into clinical trials suggests a productive and robust drug discovery engine.

The initial clinical program for HTL-0030310 was strategically focused on addressing endocrine disorders, with a particular emphasis on Cushing's disease. The therapeutic goal was to modulate the excessive release of hormones characteristic of pituitary adenomas.[7]

4. Preclinical Research and In Vitro Efficacy

The preclinical evaluation of HTL-0030310 provided foundational evidence for its potential therapeutic utility, particularly through in vitro studies on human pituitary adenoma tissues and comprehensive pharmacokinetic assessments in animal models.

Studies on Human Pituitary Adenomas (Regazzo et al., 2024)

A key study by Regazzo and colleagues, published in 2024, investigated the effects of HTL-0030310 on hormone secretion in primary cultures derived from human ACTH-secreting (n=3) and GH-secreting (n=5) pituitary adenomas.[1] In these experiments, adenoma cultures were treated with HTL-0030310 at concentrations of 1, 10, and 100 nM, both alone and in combination with CRH (for ACTH-adenomas) or GHRH (for GH-adenomas). For comparative purposes, parallel incubations with 10 nM pasireotide were also conducted. The primary readouts were ACTH, GH, and pro-opiomelanocortin (POMC) levels and gene expression.[3]

Key Findings for ACTH-Secreting Adenomas:

HTL-0030310 demonstrated notable inhibitory effects on ACTH-secreting adenomas. It reduced basal (unchallenged) ACTH secretion and POMC levels by up to 50% in two of the three adenoma specimens tested.1 Specifically, at a concentration of 100 nM, HTL-0030310 reduced POMC expression to approximately 80% of control levels.12

Perhaps more significantly, HTL-0030310 blunted CRH-stimulated ACTH and POMC secretion by 20-70% across all three specimens, with the effect appearing to be dose-dependent.1 The compound markedly reduced CRH-stimulated POMC expression by 40-60%.3 The authors noted that the inhibitory effect of HTL-0030310 on CRH-stimulated ACTH secretion was more evident than its effect on spontaneous secretion. In these in vitro assays, the inhibitory impact of pasireotide (at 10nM) on CRH-stimulated ACTH secretion appeared less pronounced than that of HTL-0030310.3 This consistent and potent inhibition of both basal and stimulated ACTH/POMC production in vitro provides a strong preclinical rationale for its potential efficacy in Cushing's disease, a condition driven by ACTH hypersecretion. The apparent superior potency to pasireotide in this specific experimental context, if translatable to the clinical setting, could signify a meaningful therapeutic advancement.

Key Findings for GH-Secreting Adenomas:

The effects of HTL-0030310 on GH-secreting adenomas were more varied. A reduction in spontaneous GH secretion was observed in four out of five adenoma cultures.1 This effect was described as "less homogeneous" compared to the findings in ACTH-secreting adenomas.1 A clear reduction in GH secretion at both 4 and 24 hours of incubation was noted in two specimens, while in two other specimens, the reduction was apparent at either the 4-hour or 24-hour time point, but not consistently at both.3 Furthermore, HTL-0030310 reduced GH secretion during GHRH co-incubation in two specimens.1 This heterogeneity in response suggests that patient-specific factors, potentially including SSTR5 expression levels or other molecular characteristics of the adenoma, might influence the efficacy of HTL-0030310 in acromegaly. Consequently, careful patient selection could be crucial if this indication is pursued further. It is noteworthy that one of the initial design objectives based on SSTR5 selectivity was the potential minimization of GH inhibition 4; thus, observing GH reduction highlights the complex interplay of receptor pharmacology and the specific therapeutic goal for different indications. For acromegaly, GH reduction is the desired outcome.

SSTR Expression:

The study by Regazzo et al. also confirmed the expression of SSTR2, SSTR3, and SSTR5 in all tested pituitary adenoma specimens. However, within this limited series, no clear correlation was apparent between the expression levels of these receptors and the observed inhibitory effect of HTL-0030310.1

Preclinical Pharmacokinetics (ADME)

Preclinical pharmacokinetic studies were conducted in rats, dogs, and cynomolgus monkeys to evaluate the absorption, distribution, metabolism, and excretion (ADME) properties of HTL-0030310.[4] These investigations revealed that HTL-0030310 possesses low clearance and a moderate to low volume of distribution, comparable to intracellular or extracellular fluid volumes. The compound exhibited a well-characterized half-life ranging from 4 to 15 hours across these animal species. These pharmacokinetic data were supportive of a potential once-daily subcutaneous (SC) dosing regimen in humans.[4] Such favorable preclinical PK characteristics—particularly low clearance and a half-life amenable to convenient dosing—are positive indicators for successful clinical translation, suggesting a manageable and patient-friendly administration schedule.

Overall Preclinical Profile

Comprehensive preclinical assessments, including extensive in vitro pharmacological profiling, in vivo efficacy studies, and in vitro/in vivo safety studies, were completed for HTL-0030310. These studies collectively established HTL-0030310 as a highly functionally selective agonist of SSTR5 over SSTR2. Beyond this key selectivity, its general somatostatin agonist signature was reported to be very similar to that of pasireotide. Importantly, no significant off-target activity was identified. This robust preclinical data package provided the necessary support for the initiation of human clinical trials.[4]

Table 2: Summary of In Vitro Efficacy of HTL-0030310 in Pituitary Adenoma Cultures (Adapted from Regazzo et al., 2024)

Adenoma Type	Condition	Hormone/Biomarker	HTL-0030310 Concentration(s)	Observed Effect (vs. Control/Stimulated)	Comparison with Pasireotide (10nM) (vs. Stimulated)
ACTH-secreting (n=3)	Basal	ACTH, POMC	1, 10, 100 nM	Up to 50% reduction in 2/3 specimens; POMC expression ~80% of control (100nM)	Not specified for basal
	CRH-stimulated	ACTH, POMC	1, 10, 100 nM	20-70% blunting of secretion in 3/3 specimens; POMC expression blunted 40-60%	Less pronounced inhibition of ACTH by pasireotide
GH-secreting (n=5)	Basal	GH	1, 10, 100 nM	Reduction in 4/5 specimens (effect less homogeneous)	Not specified for basal
	GHRH-stimulated	GH	1, 10, 100 nM	Reduction in 2/5 specimens	Not specified for stimulated

Source Data: [1]

5. Clinical Development Program: Phase 1 Studies

The entry of HTL-0030310 into human testing was marked by a Phase 1 clinical trial designed to assess its initial safety, tolerability, and pharmacokinetic/pharmacodynamic profile.

Trial Identification and Design

The Phase 1 study is identified by the ClinicalTrials.gov identifier NCT03847207 and the EudraCT number 2018-003169-33.[8] Its official title is "A Three-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of HTL0030310 in Healthy Subjects".[11] This first-in-human trial was sponsored by Sosei Heptares (Nxera Pharma UK Ltd.).[8]

The study employed a robust design: it was a double-blind, randomized, placebo-controlled trial investigating single ascending subcutaneous doses of HTL-0030310.[6] The trial was conducted in the United Kingdom and enrolled up to 64 healthy male and female adult subjects.[6]

Objectives and Outcome Measures

The primary objectives of the Phase 1 study were to evaluate the safety and tolerability of HTL-0030310.[6] Secondary objectives included the assessment of its pharmacokinetics (PK) and pharmacodynamics (PD).[6] Of particular interest within the pharmacodynamic assessments were the effects of HTL-0030310 on glucose regulation and other endocrine hormones.[7]

Timeline and Status

The Phase 1 trial was initiated with the first subject dosed on February 20, 2019 [6], with some records indicating a start date of January 23, 2019.[11] Preliminary results from this study were anticipated in the second half of 2019.[7] The trial has since been completed, with AdisInsight reporting a completion date of September 2020.[8]

Available Phase 1 Findings and Implications

While detailed numerical results from the Phase 1 trial (such as specific PK parameters in humans, quantitative PD changes, or comprehensive adverse event profiles) are not extensively available in the public domain from the provided information, a key insight into the study's outcomes was provided in an abstract from the American Chemical Society (ACS) in 2022.[4] This abstract stated: "HTL0030310 has completed a Phase 1 clinical study and the findings support its further investigation in hypoglycaemic conditions with the potential for differentiation from standard of care."

This statement strongly suggests that the pharmacodynamic markers related to glucose control (e.g., effects on insulin, glucagon, and blood glucose levels) yielded a promising signal in the healthy volunteer population. Such findings would logically lead to the exploration of HTL-0030310's utility in diseases characterized by hypoglycemia, such as congenital hyperinsulinism or certain types of reactive hypoglycemia. This potential strategic pivot or expansion towards hypoglycemic disorders represents a critical development in the drug's trajectory. It may indicate that the observed effects on glucose regulation were particularly pronounced or offered a clearer therapeutic window compared to effects on pituitary hormones in healthy subjects, or it could reflect a strategic decision by the developer based on unmet medical needs and the competitive landscape.

The lack of detailed public Phase 1 data is not uncommon for early-stage clinical programs, as companies often await further development milestones or specific scientific forums for comprehensive disclosure.

Table 3: Overview of Phase 1 Clinical Trial (NCT03847207 / EudraCT 2018-003169-33)

Feature	Description
Trial Identifiers	NCT03847207; EudraCT 2018-003169-33
Official Title	A Three-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of HTL0030310 in Healthy Subjects
Sponsor	Sosei Heptares / Nxera Pharma UK Ltd.
Phase	Phase 1
Study Design	Randomized, double-blind, placebo-controlled, single ascending dose
Population	Healthy adult volunteers (up to 64 male and female)
Intervention	HTL-0030310, subcutaneous injection
Primary Outcome Measures	Safety, Tolerability
Key Secondary Outcome Measures	Pharmacokinetics, Pharmacodynamics (including effects on glucose and other endocrine hormones)
Start Date	February 2019 (first patient dosed)
Completion Date	Reported September 2020
Reported Status	Completed
Summary of Available Findings	Findings support further investigation in hypoglycemic conditions

Source Data: [4]

6. Therapeutic Potential and Target Indications

HTL-0030310 has been investigated for its therapeutic potential across a spectrum of endocrine disorders, driven by its unique SSTR5-preferring mechanism of action.

Primary Original Focus: Cushing's Disease and Acromegaly

The initial development of HTL-0030310 centered on Cushing's disease and acromegaly.[1] This focus was predicated on the expression of SSTR5 on ACTH-secreting and GH-secreting pituitary adenomas, respectively, and the significant unmet medical need arising from the fact that approximately 30-50% of patients do not achieve adequate disease control with existing SRLs.[1] The SSTR5 selectivity of HTL-0030310 was specifically designed to modulate the excessive hormone release characteristic of these conditions.[7] The in vitro studies by Regazzo et al. provided direct support for this rationale, demonstrating inhibition of ACTH/POMC and GH secretion in cultured human pituitary adenoma cells.[1]

Emerging Focus: Hypoglycemic Disorders

A significant development in the therapeutic positioning of HTL-0030310 arose from its Phase 1 study findings, which reportedly support its further investigation in hypoglycemic conditions.[4] SSTR5 receptors are prominently expressed on pancreatic islet cells and play a crucial role in the regulation of insulin and glucagon secretion. Selective agonism of SSTR5 by HTL-0030310 could therefore offer a novel approach to managing disorders of low blood sugar. Potential mechanisms include the inhibition of excessive insulin secretion in conditions such as congenital hyperinsulinism or insulinomatosis, or the modulation of glucagon secretion to counteract hypoglycemia.

The hypothesized advantage in this setting lies in the SSTR5 selectivity, which might provide "effective hypoglycaemic control and a better side effect profile compared with non-selective somatostatin agonists used off-label".[4] For example, by preferentially targeting SSTR5, HTL-0030310 might minimize the SSTR2-mediated inhibition of glucagon (a counter-regulatory hormone that raises blood glucose), which could be detrimental if insulin secretion is also suppressed. This selective action could also avoid other side effects associated with broader SSTR2 engagement. If HTL-0030310 can effectively and selectively modulate pancreatic hormone secretion to prevent or treat hypoglycemia with an improved safety margin over existing non-selective SRLs (which can have complex and sometimes paradoxical effects on glucose metabolism), it could address a significant unmet need in this area.

Broader "Endocrine Disorders"

Early announcements regarding HTL-0030310 often referred to its potential in "endocrine disorders" more broadly [6], suggesting an initial wider scope of investigation before the focus began to narrow towards more specific pituitary or pancreatic applications based on emerging data.

Unmet Medical Needs

In both Cushing's disease and acromegaly, a substantial proportion of patients either do not respond adequately to, or cannot tolerate, current SRL therapies, underscoring the need for novel agents with different mechanisms or improved profiles.[1] Similarly, for various hypoglycemic disorders, particularly rare congenital forms, treatment options can be limited, invasive, or associated with significant adverse effects, highlighting an area where a targeted therapy like HTL-0030310 could make a meaningful impact.

7. Current Status and Future Perspectives

The clinical development of HTL-0030310 has progressed through initial human studies, but its current trajectory and primary focus require further elucidation.

Post-Phase 1 Development Status

The Phase 1 clinical trial (NCT03847207 / EudraCT 2018-003169-33) in healthy volunteers was completed, with preliminary results anticipated in the latter half of 2019 and formal completion reported around September 2020.[8] A key takeaway from this study, as indicated in a 2022 ACS abstract, was that the findings supported further investigation of HTL-0030310 in hypoglycemic conditions.[4]

Despite this promising direction, more recent database entries from AdisInsight (April 2024) and Patsnap Synapse (April 2025) list HTL-0030310 with a status of "No development reported" or "Pending Phase 1" for endocrine disorders, even while acknowledging the completion of the Phase 1 trial.[8] This apparent discrepancy could suggest a strategic pause, a de-prioritization of the pituitary indications, or a shift in focus towards hypoglycemia that has not yet been accompanied by widespread public announcements of new trial initiations by Nxera Pharma for HTL-0030310. The most recent scientific publication identified is the January 2024 paper by Regazzo et al., which details the in vitro work on pituitary adenomas.[1] This publication could represent a strategic dissemination of existing data rather than an indicator of active, ongoing clinical progression for Cushing's disease or acromegaly. The absence of explicit mentions of HTL-0030310 in recent general pipeline updates from Nxera Pharma (based on the provided snippets [15]) further contributes to the opacity regarding its current active development status. Pharmaceutical development pathways are subject to various factors including funding availability, strategic re-prioritization, the competitive landscape, and manufacturing considerations, any of which could influence the pace and direction of a program post-Phase 1.

Potential to Address Unmet Needs

Should HTL-0030310 successfully demonstrate efficacy and a favorable safety profile in future clinical trials, it holds the potential to offer a valuable new therapeutic option for patients with Cushing's disease, acromegaly, or specific hypoglycemic disorders. Its SSTR5 selectivity remains its core differentiating characteristic, which could translate into benefits for patients who do not respond well to, or cannot tolerate, existing therapies.

Future Research and Clinical Development Considerations

Advancement of HTL-0030310 would necessitate further clinical trials, typically Phase 2 studies, to establish proof-of-concept efficacy and safety in specific patient populations for any indication pursued (whether pituitary disorders or hypoglycemia). Such trials would involve careful dose-ranging evaluations and assessments of long-term safety. Given the heterogeneous responses observed in vitro for GH-secreting adenomas, the development of biomarkers (e.g., SSTR5 expression levels in target tissues) could be crucial for optimizing patient selection and predicting response. Ultimately, to establish its place in the therapeutic armamentarium, head-to-head comparative trials against existing standard-of-care SRLs or other relevant treatments would likely be required to demonstrate superiority or non-inferiority with tangible advantages.

8. Concluding Expert Assessment

HTL-0030310 emerges from the available data as a rationally designed peptide agonist characterized by its preferential selectivity for the somatostatin receptor subtype 5 (SSTR5). This distinct pharmacological profile underpins its therapeutic rationale. Preclinical in vitro investigations have demonstrated its capacity to inhibit hormone secretion from human ACTH- and GH-secreting pituitary adenomas, lending support to its initial consideration for Cushing's disease and acromegaly.

The completion of a Phase 1 clinical trial in healthy volunteers reportedly yielded findings that support the further investigation of HTL-0030310 in hypoglycemic conditions. This suggests a potentially novel and valuable therapeutic avenue, leveraging the role of SSTR5 in pancreatic islet cell function. The structure-based drug design approach employed by Sosei Heptares (now Nxera Pharma) provides a strong scientific foundation for the molecule's development.

However, several challenges and uncertainties remain. The most pressing is the need for clarification from the developer regarding the current active clinical development status of HTL-0030310 and its primary indication focus—whether it remains on pituitary disorders, has pivoted primarily to hypoglycemia, or if both are being pursued. The lack of recent, direct company communications detailing the progression of HTL-0030310 into later-phase trials is a notable point. As with all investigational agents, the successful translation of in vitro efficacy and pharmacodynamic signals observed in healthy volunteers into clinically meaningful and safe outcomes in patient populations is a critical hurdle. The heterogeneity of response observed in vitro with GH-secreting adenomas may also necessitate sophisticated patient selection strategies if acromegaly remains a target indication.

In conclusion, HTL-0030310 is an interesting therapeutic candidate with a scientifically sound basis for its SSTR5-selective mechanism. Its potential in pituitary disorders is backed by preclinical data, and the emergent possibility of addressing hypoglycemic conditions, if actively developed and validated, could fulfill a significant unmet medical need. Nonetheless, transparent updates on its clinical development pathway and more substantive clinical data are essential to fully ascertain its future therapeutic prospects.

Works cited

1. novel somatostatin receptor ligand for human ACTH – and GH –secreting pituitary adenomas | European Journal of Endocrinology | Oxford Academic, accessed May 14, 2025, https://academic.oup.com/ejendo/article/190/1/K8/7484588
2. A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas - PubMed, accessed May 14, 2025, https://pubmed.ncbi.nlm.nih.gov/38123488/
3. A novel somatostatin receptor ligand for human ... - Oxford Academic, accessed May 14, 2025, https://academic.oup.com/ejendo/article-pdf/190/1/K8/55371565/lvad171.pdf
4. Identification of subtype selective SST5 agonist peptide ..., accessed May 14, 2025, https://acs.digitellinc.com/p/s/identification-of-subtype-selective-sst5-agonist-peptide-htl0030310-using-structure-based-drug-design-476871
5. Identification of subtype selective SST5 agonist peptide ... - Morressier, accessed May 14, 2025, https://www.morressier.com/o/event/623377e0b300ee00119b311f/article/6234a17d818a915252b7f318
6. Sosei Heptares initiates clinical programme for endocrine disorders, accessed May 14, 2025, https://www.clinicaltrialsarena.com/news/sosei-heptares-endocrine-disorders-trial/
7. Sosei Heptares Starts New Clinical Development Program - PR Newswire, accessed May 14, 2025, https://www.prnewswire.com/news-releases/sosei-heptares-starts-new-clinical-development-program-300798591.html
8. HTL 0030310 - AdisInsight - Springer, accessed May 14, 2025, https://adisinsight.springer.com/drugs/800054173
9. Our life's work, is life itself - Nxera Pharma, accessed May 14, 2025, https://www.nxera.life/
10. First subject dosed in endocrine disorders trial - PharmaTimes, accessed May 14, 2025, https://pharmatimes.com/news/first_subject_dosed_in_endocrine_disorders_trial_1278864/
11. HTL-0030310 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 14, 2025, https://synapse.patsnap.com/drug/50353880c64f4a80b1264bc0e03ccf48
12. (PDF) A Novel Somatostatin Receptor Ligand for Human ACTH- and GH-secreting Pituitary Adenomas - ResearchGate, accessed May 14, 2025, https://www.researchgate.net/publication/377118943_A_Novel_Somatostatin_Receptor_Ligand_for_Human_ACTH-_and_GH-secreting_Pituitary_Adenomas
13. novel somatostatin receptor ligand for human ACTH – and GH –secreting pituitary adenomas | European Journal of Endocrinology | Oxford Academic, accessed May 14, 2025, https://academic.oup.com/ejendo/article-abstract/190/1/K8/7484588
14. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT03847207
15. FY2024 Financial Results - Investors - Nxera Pharma, accessed May 14, 2025, https://investors.nxera.life/common/pdf/2025.2.14%20FY2024%20result%20briefing_EN_v1.pdf
16. Corporate Presentation - Investors - Nxera, accessed May 14, 2025, https://investors.nxera.life/common/pdf/Corporate%20Presentation_2024Apr_EN.pdf
17. Corporate Presentation(April 2025) - Investors, accessed May 14, 2025, https://investors.nxera.life/common/pdf/Corporate_Presentation_2025April_EN_vF.pdf
18. Corporate Presentation - Investors - Nxera Pharma, accessed May 14, 2025, https://investors.nxera.life/common/pdf/Corporate_Presentation_2025Jan_EN_v2.pdf